OVERVIEW

GHRP-6 (5 mg × 10) and Ipamorelin (5 mg × 10) is a research peptide pairing designed to stimulate endogenous growth hormone (GH) release through activation of the ghrelin receptor (GHS-R1a). GHRP-6 is one of the earlier growth hormone-releasing peptides and is known for increasing pulsatile GH secretion as well as raising insulin-like growth factor-1 (IGF-1) levels downstream. It may also stimulate appetite due to its ghrelin-mimicking activity. Ipamorelin, by contrast, is considered more selective; it promotes GH release with comparatively minimal effects on cortisol, prolactin, or appetite in experimental settings. When studied together, the two peptides are thought to amplify GH pulse amplitude through complementary receptor engagement, making the blend useful in laboratory research examining hormone signaling, metabolic regulation, tissue repair, and body composition dynamics.

Despite interest in research communities, this peptide combination is not approved by the U.S. Food and Drug Administration for medical or therapeutic use. Most evidence regarding their effects comes from animal models, in vitro research, or limited human studies rather than large, well-controlled clinical trials. Products marketed with GHRP-6 and Ipamorelin are typically labeled for research use only, and manufacturing standards, purity, and dosing consistency may vary. Because long-term safety and efficacy in humans remain uncertain, self-administration outside supervised research environments carries potential health and legal risks. Individuals seeking growth hormone-related therapies should consult qualified healthcare professionals and rely on evidence-based medical treatments.